Jove
Visualize
お問い合わせ

関連する概念動画

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

314
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
314
Blinding01:11

Blinding

4.0K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
4.0K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

388
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
388
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

529
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
529
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー
  1. ホーム
  3. 安定した冠動脈疾患患者のリバロキサバンとアスピリン: 国際的,ランダム化,ダブルブラインド,プラセボ対照試験
  1. ホーム
  3. 安定した冠動脈疾患患者のリバロキサバンとアスピリン: 国際的,ランダム化,ダブルブラインド,プラセボ対照試験

関連する実験動画

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.0K

安定した冠動脈疾患患者のリバロキサバンとアスピリン: 国際的,ランダム化,ダブルブラインド,プラセボ対照試験

Stuart J Connolly1, John W Eikelboom1, Jackie Bosch2

  • 1Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.

Lancet (London, England)
|November 15, 2017

PubMed で要約を見る

まとめ
この要約は機械生成です。

リバロキサバをアスピリンに添加すると,安定した冠動脈疾患の患者における主要な血管疾患と死亡率が著しく低下しました. 血液出血のリスクを増加させながらも,この組み合わせは臨床上の純利益を示し,世界的に病気の負担を軽減する可能性を提示しました.

さらに関連する動画

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K

関連する実験動画

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.0K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K

科学分野:

  • 心血管医学
  • 薬理学について
  • 臨床試験

背景:

  • 冠動脈疾患 (CAD) は,世界の主要な死因であり,しばしば血栓性イベントが含まれています.
  • 血小板と凝固タンパク質の活性化は,CADの病原性において重要な役割を果たします.
  • 既存の治療法であるファクターXA阻害剤とアスピリンの組み合わせは,安定したCADでは研究されていません.

研究 の 目的:

  • 安定した冠動脈疾患の患者でリバロキサバンとアスピリンの併用の有効性と安全性を評価する.
  • アスピリン単独とリバロキサバン単独との併用治療を比較する.

主な方法:

  • 多センター,ダブルブラインド,ランダム化,プラセボ対照試験 (COMPASS) で,安定したCAD患者24, 824人が参加しました.
  • 患者はリバロキサバン (2. 5 mg BID) +アスピリン (100 mg QD),リバロキサバン単独 (5 mg BID),またはアスピリン単独 (100 mg QD) を投与された.
  • 主なアウトカムは心筋梗塞,脳卒中,心血管疾患による死亡でした.

主要な成果:

  • リバロキサバンとアスピリンは,アスピリンの単独投与と比較して,主要なアウトカムを有意に低下させた (HR 0. 74,p< 0. 0001).
  • リバロキサバ単独投与は,アスピリン単独投与と比較して,主治の評価を有意に改善しなかった (HR 0. 89, p=0. 094).
  • 主要な出血は,リバロキサバンとアスピリン (HR 1.66,p< 0. 0001) とリバロキサバン単独投与 (HR 1.51,p< 0. 0001) と比較して増加した.

    • 結論:

    • 安定したCAD患者のアスピリンにリバロキサバンを追加すると,主要血管疾患および死亡率が減少します.
    • 併用治療は大きな出血のリスクを高めますが,有意な臨床的利益を示しています.
    • この組み合わせは,世界中でCADの罹患率と死亡率を大幅に減らす可能性を秘めています.